25 years of CENTIS. Pandemic and Radiopharmaceuticals

25 years of CENTIS. Pandemic and Radiopharmaceuticals

J Cruz Arencibia, R Leyva Montaña, J Morín Zorrilla

Close to its 25th anniversary, CENTIS evaluates its work in the context of the disorders triggered by COVID-19. For this purpose, the situation of nuclear medicine and radiopharmacy, before and during the epidemic and their current development prospects is examined. The production of radiopharmaceuticals continues to be a consolidated global industry and although the pandemic affects this area, the presence of other diseases does not cease, so essential and critical nuclear medicine services are still needed, therefore its gradual reopening is expected. In addition, research will be taken with more strength, given that COVID-19 is so complex and associated with so many factors that it constitutes virgin terrain in perspective for diagnostic techniques in nuclear medicine. The role of therapeutic radiopharmaceuticals in an important set of diseases, especially cancer, will also remain. As a result, the Isotope Center focus its attention under good management practices, on the consolidation of the production and distribution of radiopharmaceuticals and in the development of new products. Both aspects are mainly based on two radionuclides: Tc-99m and Y-90.

2020

coronavirus, Radiofármacos, Tecnécio99, Usos Terapêuticos, radisótopos, itrio 90, producción de isótopos

Nucleus

Taylor & Francis Group

Medical physics. Medical radiology. Nuclear medicine, Nuclear engineering. Atomic power